Skip to content

Ledderhose Disease: Radiotherapy or Not?

Ledderhose Disease: Radiotherapy or Not? A Randomised, Multicentre, Prospective, Double Blind Phase III Trial Investigating the Effect of Radiotherapy on Patients With Ledderhose Disease

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03507010
Acronym
LedRad
Enrollment
84
Registered
2018-04-24
Start date
2018-01-23
Completion date
2029-03-15
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ledderhose Disease

Keywords

Radiotherapy, Pain

Brief summary

The aim of the LedRad trial is to determine the efficacy and durability of radiotherapy as treatment for patients with Ledderhose disease and to compare this to the natural course of Ledderhose disease.

Interventions

RADIATIONRadiotherapy

Patients randomized to the Radiotherapy arm will be treated with electrons and receive a total dose of 30 Gy (two separate courses of five daily fractions of 3.0 Gy each).

OTHERSham Radiotherapy

Patients randomized to the sham-radiotherapy will not be treated and the radiotherapy treatment will only be simulated.

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CollaboratorOTHER
Catharina Ziekenhuis Eindhoven
CollaboratorOTHER
Rijnstate Hospital
CollaboratorOTHER
University Medical Center Groningen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with painful Ledderhose disease. The pain score measured with the VAS score and is at least 2 on the 11-point scale (0 = no pain to 10 = worst imaginable pain). * Age ≥ 18 years * WHO performance status 0, 1 or 2 (Appendix, section 18) * Before patient randomisation, written informed consent must be given according to ICH/GCP, and WMO requirements. * Controlling the Dutch language (speaking and reading). * Able and willing to complete quality of life questionnaires in Dutch * Must be accessible for treatment follow-up

Exclusion criteria

* Surgical intervention before for Ledderhose disease * Previous radiation treatment for Ledderhose disease * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * Not able to lay prone for at least fifteen minutes * Females who are pregnant at entry or who want to become pregnant within six months.

Design outcomes

Primary

MeasureTime frameDescription
Numeric Rating Scale12 monthsDetermine pain with the Numeric Rating Scale

Secondary

MeasureTime frameDescription
Size of ledderhose nodules12 monthsDetermine the effect of radiotherapy on size of Ledderhose nodules with MRI and Ultrasound
Walking distance6, 12 and 18 monthsDetermine the effect of radiotherapy on walking distance with the 10 meter straight line walk test
Walking motion12 monthsDetermine the effect of radiotherapy on walking motion with the PEDAR-X® in shoe pressure measurement system
Number of participants with treatment-related adverse events as assessed by CTCAE v4.018 monthsAssess the safety and toxicity of radiotherapy on this population by recording the toxicity of radiotherapy during the course of radiotherapy and thereafter measured by CT-CAE 4.0.
Numeric Rating Scale6 and 18 monthsDetermine pain with the Numeric Rating Scale
Quality of life (2)6, 12 and 18 monthsAssess the impact on quality of life of radiotherapy as treatment for this study population with the brief pain inventory questionnaire
Quality of life (3)6, 12 and 18 monthsAssess the impact on quality of life of radiotherapy as treatment for this study population with the EURO-Qol-5D questionnaire
Cost-effectiveness analysis (CEA)6, 12 and 18 monthsThe economic evaluation will be performed from a societal perspective, incorporating cost of travel to the hospital and cost of absence from work as well as direct medical cost of radiotherapy (cost of irradiation and outpatient visits). Questionnaires will be used to collect data regarding health care consumption, travel and time costs, and productivity loss at study entry and at 6-month intervals thereafter. In addition to the pain scores, quality of life will be assessed at 6-month intervals using the Rand-36 questionnaire. The utilities based on the results of the questionnaire will be used in a cost-utility analysis, calculating the ratio of incremental costs versus incremental quality-adjusted life-years (QALY).
Quality of life (1)6, 12 and 18 monthsAssess the impact on quality of life of radiotherapy as treatment for this study population with RAND-36 item Health Survey questionnaire

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026